DDInter1731 DDInter1476
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3† ,5†-adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Pirbuterol
Sunitinib {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Pirbuterol
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Pirbuterol
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nadolol
Nadolol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Pirbuterol
Sunitinib {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Pirbuterol
Sunitinib {u} (Compound) causes {v} (Side Effect) Gastrointestinal pain
Gastrointestinal pain {u} (Side Effect) is caused by {v} (Compound) Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Pirbuterol
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Penbutolol
Penbutolol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Pirbuterol
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Pirbuterol
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nadolol
Nadolol {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Pirbuterol
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Penbutolol
Penbutolol {u} may lead to a major life threatening interaction when taken with {v} Salbutamol
Salbutamol {u} (Compound) resembles {v} (Compound) Pirbuterol
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) resembles Pirbuterol (Compound)
Sunitinib (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Pirbuterol (Compound)
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Pirbuterol (Compound)
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Pirbuterol (Compound)
Sunitinib (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Terbutaline (Compound) and Terbutaline (Compound) resembles Pirbuterol (Compound)
Sunitinib (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Salbutamol (Compound) and Salbutamol (Compound) resembles Pirbuterol (Compound)
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Pirbuterol (Compound)
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) resembles Terbutaline (Compound) and Terbutaline (Compound) resembles Pirbuterol (Compound)
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Salbutamol (Compound) and Nadolol may lead to a major life threatening interaction when taken with Salbutamol and Salbutamol (Compound) resembles Pirbuterol (Compound)
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol may lead to a major life threatening interaction when taken with Salbutamol and Salbutamol (Compound) resembles Pirbuterol (Compound)